Navigation Links
NIH awards WSU researcher $1.39M to study chromatin's role in cell division
Date:8/16/2011

DETROIT The National Institute of General Medical Sciences of the National Institutes of Health recently awarded Lori A. Pile, Ph.D., assistant professor of molecular cell biology in Wayne State University's College of Liberal Arts and Sciences, $1.39 million to research how the alteration of chromatin regulates cellular division and growth. The study is intended to support the development of cancer treatments currently undergoing clinical trials.

Chromatin is a DNA-protein structure that resembles a long DNA "string" wrapped around protein "beads." When certain molecules, called chromatin modifiers, react with the protein beads, the entire chromatin structure either decompresses or coils up tightly. "Chromatin modification depends on whether the proteins were acetylated or deacetylated in other words, what kind of modifier reacted with the protein," said Pile.

There are two main types of chromatin modifiers. Histone acetyltransferases (HATs) acetylate the proteins, loosening the chromatin structure. Histone deacetylases (HDACs) deacetylate and tighten DNA's grip on the proteins. A correct balance of action of these chromatin modifiers is necessary for normal cell division. Both activities are required for cells to multiply. But when the balance tips in favor of the deacetylation step, cells can multiply too much, Pile said, and cancer is often the culprit.

That is why deacetylation is being targeted by researchers looking for a way to treat patients with cancer. Yet the exact role of HDACs and deacetylation requires more in-depth exploration.

"While a number of chromatin modifiers are currently being tested as anti-cancer agents in clinical trials, the molecular mechanisms behind their cancer-killing properties are not well understood," said Pile. "Our study is anticipated to clarify these mechanisms and refine the molecular tools designed to target cancer."

These "molecular tools" are histone deacetylase inhibitors, or HDIs. To refine HDIs, Pile will uncover the mechanisms of the target, HDAC chromatin modifiers. She will test a particular HDAC called Swi-independent SIN3 and determine whether SIN3 does, in fact, regulate cell growth and multiplication and, if so, how it affects deacetylation and gene repression.

"Inhibiting HDACs, the agents that fuel unregulated cell division, is anticipated to be an effective approach to preventing cancer progression," said Pile.


'/>"/>

Contact: Julie O'Connor
julie.oconnor@wayne.edu
313-577-8845
Wayne State University - Office of the Vice President for Research
Source:Eurekalert

Related medicine news :

1. Mental Health America Encourages Journalists, Media Professionals to Submit Entries for 2010 Media Awards
2. Michael J. Fox Foundation Awards $1 Million to Drive Critical New Research Tools and Technologies in Parkinsons Drug Development
3. International Diabetes Federation awards $2 million to 9 global diabetes research projects
4. Highmark Foundation Awards $120,000 to the American Heart Association
5. Diane von Furstenberg Establishes The DVF Awards to Recognize Outstanding Women Leaders
6. Siemens Awards for Advanced Placement Honor Top U.S. Science and Math Students and Teachers
7. Awards Strengthen Stonhard's Reputation for High-Performing Floors in the World's Most Prominent Pharmaceutical Facilities
8. Michael J. Fox Foundation Awards $1.1 Million For Clinical Trial of Transdermal Nicotine as Disease-Modifying Treatment For Parkinsons
9. AADR awards the 2010 Distinguished Mentoring Award to Irwin D. Mandel
10. AADR awards the 2010 AADR William B. Clark Fellowship to Isabel Gay
11. AADR awards the 2010 Distinguished Scientist Award to John Greenspan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... 2016 , ... It is vital for any lab to secure funding, and ... team at Beckman Coulter has designed Kaluza, templates with advanced analytical tools to streamline ... operate in a GLP (Good Laboratory Practice) fashion. , With features designed to simplify ...
(Date:12/7/2016)... ... ... came time to blow out his candles on his 14th birthday, Estefano Reano had only ... team at Joe DiMaggio Children’s Hospital surprised his family with a phone call that made ... , “He was playing at home, when we got the phone call telling us there ...
(Date:12/7/2016)... ... ... One of two inventors from Glen Burnie, Md., has a granddaughter who ... is why the co-inventor and I have designed a new and better way to ... of the patent-pending AV-AIR, a device that serves as an alternative to conventional methods ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... that its fully redesigned website, which launched October 17, 2016, features comprehensive information ... design and easy-to-navigate layout. Visitors and patients can discover the latest clinical dermatology ...
(Date:12/7/2016)... City, CA (PRWEB) , ... December 07, 2016 , ... ... during the holidays and winter seasons. One major study analyzing heart attacks among ... compared to August of a given year. We would all agree of course–no time ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... PARK , Israel , December 7, 2016 ... today the signing of a memorandum of understanding with Korean company ... between the companies will assist in expediting Kadimastem,s entry into international ... innovative treatment for severe diseases in general and ALS and diabetes ... , , ...
(Date:12/7/2016)... , Dec. 7, 2016 Boehringer Ingelheim ... in patients with unresectable malignant pleural mesothelioma (MPM) ... The data, presented at the 17 th ... Vienna , showed nintedanib plus pemetrexed/cisplatin ... plus pemetrexed/cisplatin, with a significantly improved PFS (9.4 ...
(Date:12/7/2016)... , Dec. 7, 2016  Ionis Pharmaceuticals, Inc. (NASDAQ: ... will present a company overview at the BMO Capital Markets Prescriptions ... New York, NY . A live webcast of ... of the Ionis website.  The replay will be available within 48 ... ...
Breaking Medicine Technology: